

A2
A3
A4
A5
amounts include [zinc chloride] a heavy metal as said chelatable metal agent present in an amount ranging up to forty percent of said composition by weight.

13. (Amended) The composition as set forth in claim 1 wherein said chelatable metal agent is [zinc chloride] a transition metal.

15. (Amended) The composition as set forth in claim 14 wherein said gel base is a polyoxyalkylene ether derivative of propylene glycol.

30. (Amended) The method as set forth in claim 23 wherein said steps of identifying, administering, and permitting are performed with the formation of an eschar [at] limited to the lesion site.

REMARKS

Claims 1-30 are pending in the application. Claims 1, 9, 13, 15, and 30 have been amended.

The Office Action contains an election requirement. The election requirement requires Applicants to elect an enhanced combination of 8-hydroxyquinoline with one chelatable metal agent for examination on the merits and to add a claim to the elected combination. Applicants hereby elect heavy metals or compounds that contain these metals, as represented by zinc or zinc chloride. Claim 9 has, accordingly, been amended to recite the use of heavy metals. See the passage from page 3 at line 32 to page 4 at line 5 for support of the amendments to claims 9 and 13.

Moreover, Applicants are required to elect the specific medical condition that is being treated according the method claims. The election requirement appears to be one between cancer and warts. There is ambiguity in the requirement because it is unclear whether the cancer component of the election requirement pertains to both precancerous lesions and cancerous lesions. Therefore, Applicant elects the cancer portion of the requirement, and this is understood from the context of the requirement to also encompass precancerous lesions unless the Examiner wishes to expressly state a further election requirement, in which case the Applicants would again elect the treatment of cancer.